论文部分内容阅读
本文综合评价吡柔比星与表柔比星在表浅性膀胱癌术后灌注预防复发中的有效性与经济性.通过文献研究,对吡柔比星与表柔比星在表浅性膀胱癌术后灌注预防复发中的有效性进行规范化系统评价;结合专家意见、文献及获得的成本数据对吡柔比星与表柔比星进行药物经济学分析.结果表明,文献分析及专家意见都证实吡柔比星与表柔比星膀胱灌注对预防表浅性膀胱癌术后复发的效果并无差异;若按照临床实践及文献研究中常用的灌注方案进行灌注,吡柔比星与表柔比星的经济学评价需按照原研药和仿制药分别讨论,原研药吡柔比星比表柔比星更具经济学优势;仿制药表柔比星比吡柔比星更具经济学优势.吡柔比星与表柔比星膀胱灌注对预防表浅性膀胱癌术后复发的效果并无统计学差异;吡柔比星与表柔比星经济学优势需分别讨论.“,”In the present study,we aimed to evaluate the efficiency and cost of pirarubicin (THP) and epirubicin (EPI) as prophylaxis for recurrence in patients with superficial bladder tumors by bladder instillation after transurethral resection of a bladder tumor (TUR-BT).Standardized evaluation was performed by analyzing research papers.Moreover,expert opinions,studies and cost data were combined to evaluate cost of THP and EPI.With systematic review and expert opinions,we confirmed that THP and EPI were not statistically different when they were used as prophylaxis for recurrence in patients with superficial bladder tumors by bladder instillation after TUR-BT.Moreover,the cost evaluation of THP and EPI needs to be separately discussed according to original/generic drug.The original drug THP had more cost advantages than EPI,while generic EPI had more cost advantages than THP.